Hit-and-miss PhIIIs leave Lundbeck and Otsuka’s latest Alzheimer’s program in a precarious position
Seven months after Lundbeck and Otsuka reported a Phase III flop for their Alzheimer’s drug idalopirdine, the partners are back with a hit-and-miss score on easing Alzheimer’s agitation for their blockbuster therapy Rexulti (brexpiprazole).
Already approved for schizophrenia and major depression, the collaborators were looking for the first approval of an antipsychotic specifically for agitation triggered by Alzheimer’s dementia, a condition that afflicts millions of people in the US and millions more worldwide. Agitation can be expressed in many ways, running from wandering to aggressive behavior.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.